vzphotos/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) shares traded higher in the premarket on Friday after the maker of Humira arthritis therapy raised its full-year profit outlook following a strong Q1 that exceeded Wall Street’s estimates thanks to the company’s newer immunology drugs.
The North